High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.

High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.

Prostate cancer is a heterogeneous group of diseases and there is a need for more efficient and targeted methods of treatment. In this study, the potential of gene expression data and RNA interference technique were combined to advance future personalized prostate cancer therapeutics. To distinguish...

Full description

Bibliographic Details
Main Authors: Paula Vainio, John-Patrick Mpindi, Pekka Kohonen, Vidal Fey, Tuomas Mirtti, Kalle A Alanen, Merja Perälä, Olli Kallioniemi, Kristiina Iljin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22761906/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22761906/pdf/?tool=EBI

Similar Items